We are enthusiastic to announce that our joint research with Variational AI will be featured at the upcoming Discovery on Target 2025 Conference, taking place in Boston, MA, USA, September 22–25.
This Conference is a leading event dedicated to “hot” drug targets and innovative approaches in drug discovery, bringing together experts in cancer therapies, AI/machine learning, protein degradation, synthetic biology, translational models, and more.
We warmly invite you to explore the poster: “Discovery of Novel Dual EGFR/FGFR1 Inhibitors via AI-driven Design and Synthesis,” highlighting the successful collaboration between Life Chemicals and Variational AI that has revealed an unparalleled potential of combining cutting-edge AI methods and state-of-the-art chemistry to accelerate the discovery of innovative therapeutic solutions.
The project will be presented by our partners from Variational AI attending this premier gathering. Don’t miss a good opportunity to advance your insight into dual kinase inhibition research and open up new horizons of AI-driven medchem innovations!
|
|
Please contact us at marketing@lifechemicals.com for additional information and collaboration opportunities. |
